Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 0.3% - Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares rose 0.3% on Wednesday . The stock traded as high as $6.72 and last traded at $6.49. Approximately 6,993,546 shares changed hands during trading, a decline of 73% from the average daily volume of 25,691,047 shares. The stock had previously closed at $6.47.

Wall Street Analysts Forecast Growth

RXRX has been the subject of a number of recent research reports. KeyCorp dropped their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $8.25.

Recursion Pharmaceuticals Stock Up 5.6 %

The company's fifty day moving average price is $7.64 and its 200-day moving average price is $7.07. The stock has a market cap of $2.57 billion, a P/E ratio of -4.31 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Remove Ads

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The firm had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals's revenue was down 57.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.42) EPS. Equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently made changes to their positions in RXRX. Decker Retirement Planning Inc. bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth about $26,000. Private Trust Co. NA bought a new stake in Recursion Pharmaceuticals during the 4th quarter valued at about $27,000. GAMMA Investing LLC lifted its holdings in Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after buying an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after buying an additional 4,091 shares in the last quarter. Finally, KBC Group NV lifted its holdings in Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company's stock valued at $50,000 after buying an additional 3,377 shares in the last quarter. Institutional investors own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.